99 related articles for article (PubMed ID: 20447689)
1. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).
Kastritis E; Kyrtsonis MC; Hadjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas C; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA;
Leuk Res; 2010 Oct; 34(10):1340-3. PubMed ID: 20447689
[TBL] [Abstract][Full Text] [Related]
2. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
Kastritis E; Zervas K; Repoussis P; Michali E; Katodrytou E; Zomas A; Simeonidis A; Terpos E; Delimbassi S; Vassou A; Gika D; Dimopoulos MA;
Clin Lymphoma Myeloma; 2009 Mar; 9(1):50-2. PubMed ID: 19362972
[TBL] [Abstract][Full Text] [Related]
3. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
Merlini G; Baldini L; Broglia C; Comelli M; Goldaniga M; Palladini G; Deliliers GL; Gobbi PG
Semin Oncol; 2003 Apr; 30(2):211-5. PubMed ID: 12720138
[TBL] [Abstract][Full Text] [Related]
5. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
6. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
7. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Baek JH; Park JH; Song MK; Chung JS; Won JH; Lee SM; Joo YD; Kim YK; Kim HJ; Jo DY; Sohn SK
Ann Hematol; 2010 Jul; 89(7):681-9. PubMed ID: 20237926
[TBL] [Abstract][Full Text] [Related]
9. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
10. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L; Goldaniga M; Guffanti A; Broglia C; Cortelazzo S; Rossi A; Morra E; Colombi M; Callea V; Pogliani E; Ilariucci F; Luminari S; Morel P; Merlini G; Gobbi P
J Clin Oncol; 2005 Jul; 23(21):4662-8. PubMed ID: 16034042
[TBL] [Abstract][Full Text] [Related]
12. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
[TBL] [Abstract][Full Text] [Related]
13. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.
Turen S; Ozyar E; Altundag K; Gullu I; Atahan IL
Cancer Invest; 2007 Aug; 25(5):315-21. PubMed ID: 17661206
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
[TBL] [Abstract][Full Text] [Related]
15. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
17. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
[TBL] [Abstract][Full Text] [Related]
18. Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
Lévy V; Morel P; Porcher R; Chevret S; Wattel E; Leblond V
Haematologica; 2005 Feb; 90(2):279-81. PubMed ID: 15710594
[TBL] [Abstract][Full Text] [Related]
19. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K
Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029
[No Abstract] [Full Text] [Related]
20. Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital.
Hensel M; Brust J; Plöger C; Schuster D; Memmer ML; Franz-Werner J; Feustel HP; Karcher A; Fuxius S; Mosthaf FA; Rieger M; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Dec; 91(12):1923-8. PubMed ID: 22895554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
